Evaluation of HTLV-1 activity in HAM/TSP patients using proviral load and Tax mRNA expression after In Vitro lymphocyte activation

Document Type : Original Article


1 Microbiology and Virology Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran Virology Department, Public Health School, Tehran University of Medical Sciences, Tehran, Iran

2 Immunology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Inflammation and Inflammatory diseases Research Center, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran

4 Virology Department, Public Health School, Tehran University of Medical Sciences, Tehran, Iran


Objective(s):HTLV-1 is the first human retrovirus that has been recognized and is associated with HAM/TSP and ATLL. Studies have shown that less than five percent of HTLV-1 infected carriers develop HAM/TSP or ATLL and about ninety-five percent remain asymptomatic. Therefore, the proviral load with Tax may affect cellular genes such as cytokines and oncogenes, as well as involve in pathogenicity.
Materials and Methods:Thirty HAM/TSP patients, thirty HTLV-1 healthy carriers, and MT-2 cell line were evaluated for HTLV-1 activity. PBMCs were isolated and activated using PMA and ionomycine. Real-time PCR and TaqMan methods were performed using specific primers and fluorescence probes for Tax expression and proviral load assessment. Β2microglobulin (β2m) and albumin were used as controls in Tax expression and in proviral load, respectively.
Results: An insignificant increase in Tax expression was observed in rest PBMCs of HAM/TSP patients compared to healthy carriers. However, after lymphocyte activation there was a significant increase in Tax expression in HAM/TSP patients (P=0.042). The Proviral load in patients was significantly higher than in carriers. Moreover, there was a significant correlation between Tax mRNA expression in activated PBMCs and proviral load (R=0.37, P=0.012).
Conclusion: Although proviral load had been addressed as a valuable index for monitoring HTLV-1 infected subjects, the results of this study demonstrated that Tax expression in activated PBMCs along with proviral load assessment in HAM/TSP patients are a more reliable factor for determining the prognosis and monitoring healthy carriers and HAM/TSP patients.


1. Rezaee SA, Fazly Bazzaz BS. The significance of  HTLV-I in molecular oncology. Iran J Basic Med Sci 2013; 3:178.
2. Rafatpanah H, Rezaee A, Etemadi M, Farid Hossseini R, Khorram B, Afsahr L, et al. The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1 associated myelopathy in northeast of Iran. J Neuroimmunol 2012; 250:87-93.
3. Franchini G. Molecular mechanisms of humanT-cell leukemia/ lymphotropic virus type I infection. Blood 1995; 86:3619–3639.
4.  Vakili R,  Sabet F,  Ahmadi Ghezeldasht S, Boostani R,  Rafatpanah H, Shamsian A, et al. Human T-lymphotropic virus type I (HTLV-I) proviral load and clinical features in Iranian HAM/TSP patients. Iran J Basic Med Sci 2013; 16:268-272.
5. Yakova M, Lezin A, Dantin F, Lagathu G, Olindo S, Jean-Baptiste G, et al. Increased  proviral load in HTLV-1-infected patients with rheumatoid arthritis or connective tissue disease. Retrovirology 2005; 2:4.
6. Manns A, Hisada M, LaGrenade L. HumanT-lymphotropicvirus type I infection. Lancet 1999; 353:1951–1958.
7. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S, Sohgandi L, Azarpazhooh MR, Rezaee SA, Farid R, Bazarbachi A. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol. 2011 Nov; 52:172-176.
8. Yamano Y, Nagai M, Brennan M, Mora CA, Soldan SS, Tomaru U, et al. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8 T cells, and disease severity in− HTLV-1 associated myelopathy (HAM/TSP) . blood 2002; 99:88 94.
9. Mortreux F, Gabet AS, Wattel E. Molecular and cellular aspects of HTLV-associated leukemo genesis in vivo. Leukemia 2003; 17:26–38.
10. Jacobson S, Zaninovic V, Mora C, Rodgers-Johnson P, Sheremata WA, Gibbs CJ Jr, et al. Immunological findings in neurological diseases associated with antibodies to HTLV-I: activated lymphocytes in tropical spastic paraparesis. Ann Neurol 1988; 23:S196–200.
11. Jacobson S, Gupta A, Mattson D, Mingioli E, Mc-Farlin DE. Immunological studies intropical spastic paraparesis. Ann Neurol 19990; 27:149-156.
12. Nyborg JK, Dynan WS. Interaction of cellular proteins with the human Tcell leukemi a virus type I transcriptional control region. Purification of cellular proteins that bind the 21-base pair repeat elements. J Biol Chem 1990; 265:8230–8236.
13. Masuda ES, Imamura R, Amasaki Y, Arai,and K, Arai N. Signalling in to the T-cell nucleus: NFAT regulation. Cell Signal 1998; 10:599–611.
14. Hatanaka M, Kobayashi N. The pX region of HTLV-I. Princess Takamatsu Symp 1984; 15:205-217.
15. Bindhu M, Nair A, Lairmore MD. Role of accessory  proteins of HTLV-1 in viral replication, T cell activation, and cellular gene expression. Front Biosci 2004; 9:2556-2576.
16. Pique C, Dokhelar MC. In vivo production of proteins of HTLV type1: evidence from cytotoxic Tlymphocytes. AIDS Res Hum Retroviruses  2000; 16:1783–1786.
17. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of typeC retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneousT-cell lymphoma. Proc Natl Acad Sci USA 1980; 77:7415–7419.
18. Manns A, Miley WJ, Wilks RJ, Morgan OS, Hanchard B, Wharfe G, et al. Quantitative proviral DNA and antibody levels in the natural History of HTLV-1 infection. J Infect Dis 1999; 180:1487-1493.
19. Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, et al. Analysis of HTLV-1 proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-1 carriers:high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998; 4:586-593.
20.  Iwanaga M, Watanabe T, Utsunomiya T, Okayama M, Uchimaru K, Koh KR, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 2010; 116:1211-1219.
21. Goncalves DU, Proietti FA, Barbosa Stancioli EF, Martins ML, Ribas JG, Martins Filho OA, et al. HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) inflammatory network. Inflamm Allergy Drug Targets 2008; 7:98-107
22. Izumo S. Neuropathology of HTLV-1-associated myelopathy (HAM/TSP). Neuropathology 2010; 30:480.
23. Rios Grassi MF, Olavarria VN, Kruschewsky RdA, Mascarenhas RE, Dourado I, Correia LCL,                       et al.  Human T Cell lymphotropic virus type 1  (HTLV-1) proviral load of HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP. J Med Virol 2011; 83:1269-1274.
24. Matsuura E, Yamano Y, Jacobson S. Neuroimmunity of HTLV-I Infection. J Neuroimmune Pharmacol 2010; 5:310-325.
25. Miyoshi I, Kubonishi I,Yoshimoto S, Akagi T, Ohtsuki Y, Shiraishi Y, et al. TypeC virus particles in acord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic Tcells. Nature 1981; 294:770-771.
26. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of typeC retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77:7415-7419.
27. Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G, Zumla A. Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques 2004; 37:112-114, 116,118-119.
28. Dehee A, Cesaire R, Desire N, Lezin A, Bourdonne O, Bera O, et al. Quantification of HTLV-I proviral load by a TaqMan real-time PCR assay. J Virol Methods 2002; 102:37-51.
29. Kalavi Kh, Moradi A, Tabarraei A. Population based sero prevalence of HTLV-I infection in Golestan Province, South East of Caspian Sea, Iran. Iran J Basic Med Sci 2013; 16:225-228.
30. Lin HC, Dezzutti CS, Lal RB, Rabson AB.  Activation of human T-cell leukemia virus type 1 tax gene expression in chronically infected T cells. J Virol 1998; 72:6264–6270.
31. Lin HC, Hickey M, Hsu L, Medina D, Rabson AB.
Activation of human T cell leukemia virus type 1 LTR promoter and cellular promoter elements by T cell receptor signaling and HTLV-1 Tax expression. Virology 2005; 339:1–11.
32. Lin HC, Charlene S, Dezzutti, Renu B. Lal,A, Rabson AB.  Activation of Human T-Cell leukemia virus type 1 tax gene expression in chronically infected T Cells. J Virol 1998; 7:6264–6270.
33. Furukawa Y, Saito M, Matsumoto W, Usuku K, Tanaka Y, Izumo S, et al. Different cytokine production in tax-expressing cells between patients with human T cell lymphotropic virus type I (HTLV-I)–associated myelopathy/tropical spastic paraparesis and asymptomatic HTLV-I carriers. J Infect Dis 2003; 187:1116–1125.
34. Best I, Adaui V, Verdonck K, González E, Tipismana M, Clark D, et al.  2Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru.  Clin Exp Immunol 2006; 146:226–233.
35. Barmak K, Harhaj E, Grant C, Alefantis T, Wigdahl B. Human T cell leukemia virus type I-induced disease: pathways to cancer and neurodegeneration. Virology 2003; 308:1-12.
36. Bangham CR, Hall SE, Jeffery KJ, Vine AM, Witkover A, Nowak MA, et al. Genetic control and dynamics of the cellular immune response to the human T-cell leukaemia virus, HTLV-I. Philos Trans R Soc Lond B Biol Sci 1999; 354:691- 700.
37. Akagi T, Ono H, Nyunoya H, Shimotohno K.  Characterization of peripheral blood T-lymphocytes transduced with HTLV-1 Tax mutants with different trans-activating phenotype. Oncogene 1997; 14:2071–2078.
38. Grassmann R, Dengler C, Muller-Fleckenstein I, Fleckenstein B, McGuire K, Dokhelar MC, Sodroski JG, Haseltine WA. Transformation to continuous growth of primary human T lymphocytes by human T-cell leukemia virus type 1 X-region genes transduced by a herpesvirus saimiri vector. Proc Natl Acad Sci USA 1989; 86:3351–3355.